Generic Troxyca ER Availability
Last updated on Sep 11, 2024.
Troxyca ER is a brand name of naltrexone/oxycodone, approved by the FDA in the following formulation(s):
TROXYCA ER (naltrexone hydrochloride; oxycodone hydrochloride - capsule, extended release;oral)
-
Manufacturer: PFIZER
Approval date: August 19, 2016
Strength(s): 1.2MG;10MG (discontinued), 2.4MG;20MG (discontinued), 3.6MG;30MG (discontinued), 4.8MG;40MG (discontinued), 7.2MG;60MG (discontinued), 9.6MG;80MG (discontinued)
All of the above formulations have been discontinued.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Troxyca ER. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Patent 7,815,934
Patent expiration dates:
- December 12, 2027✓
- December 12, 2027
-
Sequestering subunit and related compositions and methods
Patent 8,685,443
Issued: April 1, 2014
Inventor(s): Boehm Garth
Assignee(s): Alpharma Pharmaceuticals LLCA sequestering subunit comprising an aversive agent and a blocking agent, wherein the blocking agent substantially prevents release of the aversive agent from the sequestering subunit in the gastrointestinal tract for a time period that is greater than 24 hours; a composition comprising a sequestering subunit in releasable form, wherein, optionally, the mechanical fragility of the sequestering subunit is the same as the mechanical fragility of the therapeutic agent in releasable form; a capsule or tablet comprising a sequestering subunit and a therapeutic agent; and a method of preventing abuse of a therapeutic agent.
Patent expiration dates:
- July 3, 2025✓
- July 3, 2025
More about Troxyca ER (naltrexone / oxycodone)
- Troxyca ER consumer information
- Check interactions
- Compare alternatives
- Imprints, shape & color data
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: narcotic analgesic combinations
Related treatment guides
Glossary
Term | Definition |
---|---|
Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.